VB0004
/ Vectus Biosystems
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 27, 2023
First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk
(clinicaltrials.gov)
- P1 | N=88 | Recruiting | Sponsor: Syneos Health | Trial completion date: Jan 2023 ➔ Jan 2024 | Trial primary completion date: Oct 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Cardiovascular • Hypertension
April 27, 2022
First-in-Human Study of VB0004 in Healthy Subjects and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk
(clinicaltrials.gov)
- P1 | N=88 | Recruiting | Sponsor: Syneos Health | Trial completion date: May 2022 ➔ Jan 2023 | Trial primary completion date: Nov 2021 ➔ Oct 2022
Trial completion date • Trial primary completion date • Cardiovascular • Hypertension
1 to 2
Of
2
Go to page
1